Suppr超能文献

激活和抑制 p90 核糖体 S6 激酶的 C 端激酶结构域。

Activation and inhibition of the C-terminal kinase domain of p90 ribosomal S6 kinases.

机构信息

Department of Molecular Biology and Genetics, DANDRITE - Nordic EMBL Partnership for Molecular Medicine, Aarhus University, Aarhus C, Denmark.

Department of Clinical Medicine- The Department of Dermatology and Venereology, Aarhus N, Denmark.

出版信息

Life Sci Alliance. 2023 Feb 20;6(5). doi: 10.26508/lsa.202201425. Print 2023 May.

Abstract

The p90 ribosomal S6 kinases (RSKs) contain two distinct catalytic kinase domains, the N-terminal and C-terminal kinase domains (NTKD and CTKD, respectively). The activation of CTKD is regulated by phosphorylation by extracellular signal-regulated kinase (ERK1/2) and an autoinhibitory αL helix. Through a mutational series in vitro of the RSK CTKDs, we found a complex mechanism lifting autoinhibition that led us to design constitutively active RSK CTKDs. These are based on a phosphomimetic mutation and a C-terminal truncation (e.g., RSK2 T577E D694*) where a high activity in absence of ERK phosphorylation is obtained. Using these constructs, we characterize IC values of ATP-competitive inhibitors and provide a setup for determining specificity constants (k/K) of covalent CTKD inhibitors.

摘要

p90 核糖体 S6 激酶 (RSKs) 包含两个独特的催化激酶结构域,即 N 端激酶结构域 (NTKD) 和 C 端激酶结构域 (CTKD)。CTKD 的激活受到细胞外信号调节激酶 (ERK1/2) 和自身抑制的 αL 螺旋的磷酸化调控。通过体外对 RSK CTKDs 的突变系列研究,我们发现了一种解除自身抑制的复杂机制,从而设计了组成型激活的 RSK CTKDs。这些构建体基于磷酸模拟突变和 C 端截断(例如,RSK2 T577E D694*),在没有 ERK 磷酸化的情况下获得高活性。使用这些构建体,我们对 ATP 竞争抑制剂的 IC 值进行了表征,并提供了确定共价 CTKD 抑制剂特异性常数 (k/K) 的方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ac5/9941302/401595c79f11/LSA-2022-01425_Fig1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验